Retatrutide vs Tirzepatide

Eli Lilly appears to be competing with itself. Tirzepatide—marketed as Mounjaro for diabetes and Zepbound for obesity—proved that dual GIP/GLP-1 receptor agonism could outperform single-target GLP-1 drugs. Now the same company is advancing retatrutide, a triple agonist that adds glucagon receptor activation to the same GIP/GLP-1 foundation.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes (2022) and chronic weight management (2023). In the SURMOUNT-1 trial, tirzepatide 15 mg produced approximately 22.5% body weight loss over 72 weeks—better than a fifth of starting weight [PMID: 35658024]. It works by activating GIP receptors (which raise insulin release and fat burning) and GLP-1 receptors (which cut appetite and slow the stomach).

Retatrutide keeps this GIP/GLP-1 base and adds a third target: the glucagon receptor. Glucagon is a hormone. In Phase 2 trials, retatrutide 12 mg achieved approximately 24.2% weight loss over just 48 weeks—nearly a quarter of starting body weight [PMID: 37366315]. The glucagon part may raise resting energy use, help the liver burn fat, and turn white fat into brown fat.

The comparison isn't simply triple beats dual. Tirzepatide has years of real-world safety data and regulatory approval across multiple indications. Retatrutide's extra receptor may raise risk in long use. Let's see how they compare.

Tirzepatide uses two targets: the GIP receptor and the GLP-1 receptor. GIP is a short gut hormone. GLP-1 is another gut hormone. GIP raises insulin release when glucose is high. It also helps fat tissue and raises fat burning. GLP-1 cuts appetite through the brain. It slows the stomach and lowers liver glucose output [PMID: 35441470]. The peptide binds albumin. This gives it a five-day half-life, so once-weekly shots work.

Retatrutide uses the same two targets and adds a third: the glucagon receptor. Each target adds its own effect. GLP-1 cuts appetite and raises insulin, same as tirzepatide. GIP raises fat burning and may ease GLP-1 nausea. Glucagon may raise resting energy use and help the liver burn fat [PMID: 37385280].

Glucagon is the key difference. On its own, it raises blood glucose. But with GLP-1 and GIP active, glucose stays steady. GLP-1 and GIP mostly cut food intake. They do not raise energy use much. Retatrutide's glucagon target may change that. This may explain its faster weight loss.

Both are peptides given as weekly shots under the skin. Both come from Eli Lilly. Their drug profiles look similar. Retatrutide's third target may change how it spreads in the body. That is not fully mapped in published data.

Retatrutide and tirzepatide come from Eli Lilly. Both target the GIP receptor and the GLP-1 receptor. Both cut appetite through the brain. Both raise insulin release from the pancreas. Both are weekly shots under the skin.

Both go past single-target GLP-1 drugs like semaglutide. Both use the GIP receptor to raise fat burning. Both show better blood sugar control, less liver fat, and better heart risk markers in trials.

Both are synthetic peptides with albumin-binding tweaks. This gives them long half-lives for weekly shots. Both target obesity and type 2 diabetes. Both show that multi-target drugs beat single-target drugs. The open question is how many targets are best.

The main difference is the glucagon receptor. Tirzepatide targets two receptors: GIP and GLP-1. Retatrutide targets three: GIP, GLP-1, and glucagon. This adds a whole new path for metabolic effects.

The weight loss data hints that the extra target matters. Tirzepatide 15 mg gave ~22.5% weight loss over 72 weeks in SURMOUNT-1 [PMID: 35658024]. Retatrutide 12 mg gave ~24.2% over just 48 weeks in its Phase 2 trial [PMID: 37902090]. The faster, larger loss may come from higher energy use via glucagon. Tirzepatide alone cannot do this.

The key is energy balance. Tirzepatide works mainly on the intake side: less appetite and less food. Retatrutide does this too via GLP-1. But it also works on the output side: glucagon may raise resting metabolic rate, help the liver burn fat, and turn white fat into brown fat.

Their approval stage differs. Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro, 2022) and obesity (Zepbound, 2023). It has years of real-world safety data. Retatrutide is still in Phase 3 trials with no approved uses. Long-term safety of chronic glucagon receptor activation in humans is not yet established. Early data suggests acceptable tolerability, but years of real-world data will be needed to match tirzepatide's safety evidence base.

Side effect profiles overlap: gut issues top both lists. Retatrutide may cause less nausea at strong doses. GIP may ease GLP-1 nausea. But glucagon may raise heart rate and affect liver glucose. No signal has stopped trials so far. But these points help explain why risk-sensitive work still defaults to tirzepatide's better-mapped safety track.

Pick tirzepatide if your work needs an approved, well-studied dual-target peptide with real-world safety data spanning millions of patient-years. It is the top standard for multi-receptor weight loss therapy. If you need a peptide with known pharmacokinetics, known drug interactions, and regulatory approval for both diabetes and obesity, tirzepatide is the proven pick. Its GIP/GLP-1 base does much better than single-target GLP-1 drugs. It skips the unknowns of long-term glucagon activation.

Pick retatrutide if your work asks how the glucagon receptor helps weight control, energy use, or liver fat. Retatrutide lets you test whether adding energy output (via glucagon) to lower food intake (via GLP-1/GIP) changes the outcome. If you care about fat browning, resting metabolic rate, or how all three gut hormone receptors interact, retatrutide offers paths tirzepatide cannot reach.

For head-to-head work, the pair is very useful. Tirzepatide is the dual-target control. Retatrutide is the triple-target test. The gap between them isolates what the glucagon receptor adds. This is the newest and least-known piece in the multi-target space.